This study focuses on the discovery of protein biomarkers for the early diagnosis of gastric cancer and the development of corresponding detection methods. By employing advanced mass spectrometry-based proteomic technologies, the investigators conducted an in-depth analysis of a large cohort of clinical samples to identify specific protein biomarkers capable of accurately distinguishing gastric cancer patients from healthy individuals. The findings from this research are expected to facilitate the development of novel non-invasive or minimally invasive diagnostic approaches, thereby improving early detection, enhancing patient prognosis, and increasing survival rates.
Male or female, aged ≥18 and ≤95 years.
Histopathologically confirmed gastric cancer, as defined by the 2024 edition of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer.
No prior anti-tumor treatment (including radiotherapy, chemotherapy, targeted therapy, or immunotherapy).
Availability of complete clinicopathological data and follow-up information.
History of prior malignancy or cancer treatment.
Presence of concurrent malignancies of other types.
Inability to tolerate gastroscopy.
The study recruits two main populations: patients with gastric cancer and non-gastric cancer participants. The latter group includes two subgroups: individuals with precancerous gastric lesions and healthy controls.
Cohort
Prospective
Not listed
Diagnostic Performance of the Serum Protein Biomarker-Based Model for Gastric Cancer
Evaluation of the sensitivity and specificity of a diagnostic model constructed using key serum protein biomarkers for the early detection of gastric cancer.
Predictive performance of the serum protein model for the progression risk from precancerous gastric lesions to gastric cancer
Predictive performance of the serum protein model for the progression risk from precancerous gastric lesions to gastric cancer, evaluated by prediction accuracy and area under the ROC curve (AUC).
Predictive performance of the serum protein model for response to neoadjuvant therapy in gastric cancer
Predictive performance of the serum protein model for response to neoadjuvant therapy in gastric cancer, assessed by prediction accuracy and AUC.
Prognostic performance of the serum protein model in gastric cancer patients
Prognostic performance of the serum protein model in gastric cancer patients, measured by prediction accuracy and AUC.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
